Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
EU drugs regulator backs higher dose of Novo's Wegovy
09:30am, Friday, 12'th Dec 2025
Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)
Novo Nordisk Launches $24 a Week Ozempic in This Country. Why the Big Price Cut.
07:41am, Friday, 12'th Dec 2025
Americans without health insurance could be paying more than 10 times as much for the weight-loss drugs.
Novo Nordisk Launches Ozempic in India at $24 a Week
06:33am, Friday, 12'th Dec 2025
Novo Nordisk (NVO, Financials) has brought its blockbuster diabetes medicine Ozempic to India, where the lowest weekly dosage costs around $24. The company hope
Novo Nordisk launches blockbuster diabetes drug Ozempic in India
01:41am, Friday, 12'th Dec 2025
Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on Friday.
Why Novo Nordisk Stock Topped the Market on Thursday
07:54pm, Thursday, 11'th Dec 2025
A bipartisan bill has been introduced in the U.S. Congress that would curb some activities of compound pharmacies. The maker of Wegovy has been particularly affected by competition from such parties.
Novo Nordisk (NVO) Laps the Stock Market: Here's Why
06:46pm, Thursday, 11'th Dec 2025
Novo Nordisk (NVO) closed at $50.29 in the latest trading session, marking a +2.53% move from the prior day.
Market Today: Fed Cut, Oracle Slide, Broadcom AI Surge
05:35pm, Thursday, 11'th Dec 2025
Stock News Oracle sinks, ripples across AI trade: Oracle (ORCL) fell about 11% after a revenue miss and heavier AI capex drove negative free cash flow, pressuri
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
07:39am, Thursday, 11'th Dec 2025
Ahead of its Capital Markets Day Thursday, Zealand Pharma unveiled its "Metabolic Frontier 2030" strategy. The strategy comes as Zealand shares have dropped 29% year to date, with investors betting on
3 Absurdly Cheap Stocks That Look Like Steals Right Now
12:22pm, Wednesday, 10'th Dec 2025
UPS, Novo Nordisk, and Adobe are all trading well below the S&P 500's average price-to-earnings ratio. Their underlying businesses are solid and profitable.
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
11:20am, Wednesday, 10'th Dec 2025
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk
09:39am, Wednesday, 10'th Dec 2025
Novo Nordisk (NVO) appears undervalued relative to Big Pharma peers, especially given its superior long-term growth and profitability metrics outside of recent setbacks. NVO's two-thirds market cap de
Archon Partners LLC Raises Stake in Novo Nordisk A/S $NVO
03:25am, Wednesday, 10'th Dec 2025
Archon Partners LLC boosted its holdings in Novo Nordisk A/S (NYSE: NVO) by 55.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 140,000
Why Novo Nordisk Stock Was Melting on Monday
03:16pm, Monday, 08'th Dec 2025
The Wegovy and Ozempic maker was hit with an analyst recommendation downgrade. A onetime bull now feels the stock is only a hold.
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?
11:05am, Friday, 05'th Dec 2025
Novo Nordisk's semaglutide failed in pivotal studies as a treatment for Alzheimer's disease. This isn't a significant obstacle to the drugmaker's prospects, despite what the market reaction suggests.
